Donald R. Johns

发表

Activity of secukinumab, an anti-IL-17A antibody, on brain lesions in RRMS: results from a randomized, proof-of-concept study

R. P. Maguire, H. Garren, E. Havrdová, 2016, Journal of Neurology.

Sébastien Jacquemont Associated with Differential Response to the mGluR 5 Antagonist AFQ 056 Gene in Fragile X Syndrome Is FMR 1 Epigenetic Modification of the

J. Beckmann, N. Hadjikhani, Joanne M. Meyer, 2010 .

ACh receptor partial agonist: pharmacological characterization and phase I

D. Hoyer, G. Bilbe, C. Pryce, 2015 .

Efficacy and safety of single- and repeated-selurampanel dosing for 2 weeks in patients with chronic subjective tinnitus: Results of a randomized, double-blind, placebo-controlled, cross-over, proof-of-concept phase IIa study.

B. Langguth, O. Sverdlov, F. Wagner, 2021, Progress in brain research.

The acute antiparkinsonian and antidyskinetic effect of AFQ056, a novel metabotropic glutamate receptor type 5 antagonist, in L-Dopa-treated parkinsonian monkeys.

L. Grégoire, F. Gasparini, T. Di Paolo, 2011, Parkinsonism & related disorders.

Antagonism of mGluR5 in Fragile X: A Randomized, Placebo-Controlled, Proof-of-Concept Study of AFQ056, a Novel, Sub-Type Selective mGluR5 Antagonist

J. Beckmann, N. Hadjikhani, Joanne M. Meyer, 2011 .

Randomized, multicenter trial to assess the efficacy, safety and tolerability of a single dose of a novel AMPA receptor antagonist BGG492 for the treatment of acute migraine attacks

H. Diener, A. Straube, S. Evers, 2014, Cephalalgia : an international journal of headache.

Epigenetic Modification of the FMR1 Gene in Fragile X Syndrome Is Associated with Differential Response to the mGluR5 Antagonist AFQ056

Janice Branson, Jacques S. Beckmann, Nouchine Hadjikhani, 2011, Science Translational Medicine.

First-in-Man Intrathecal Application of Neurite Growth-Promoting Anti-Nogo-A Antibodies in Acute Spinal Cord Injury

A. Curt, R. Rupp, M. Schwab, 2018, Neurorehabilitation and neural repair.

Treatment of Levodopa-Induced Dyskinesias : Results of 2 Randomized Controlled Trials

Daniela Berg, Maria Stamelou, Marc Vandemeulebroecke, 2011 .

Mavoglurant Augmentation in OCD Patients Resistant to Selective Serotonin Reuptake Inhibitors: A Proof-of-Concept, Randomized, Placebo-Controlled, Phase 2 Study

Dan J Stein, M. Fava, G. Hasler, 2017, Advances in Therapy.

Metabotropic glutamate receptor type 5 in levodopa-induced motor complications

L. Grégoire, O. Hornykiewicz, F. Gasparini, 2011, Neurobiology of Aging.

AFQ056 treatment of levodopa‐induced dyskinesias: Results of 2 randomized controlled trials

J. Godau, H. Huber, B. Gomez-Mancilla, 2011, Movement disorders : official journal of the Movement Disorder Society.

A Placebo‐Controlled Trial of AQW051 in Patients With Moderate to Severe Levodopa‐Induced Dyskinesia

L. Defebvre, I. Rozenberg, O. Rascol, 2016, Movement Disorders.

AQW051, a novel, potent and selective α7 nicotinic ACh receptor partial agonist: pharmacological characterization and phase I evaluation

D. Hoyer, G. Bilbe, K. Lingenhoehl, 2015, British journal of pharmacology.

Dose titration of BAF312 attenuates the initial heart rate reducing effect in healthy subjects.

E. Legangneux, A. Gardin, Donald R. Johns, 2013, British journal of clinical pharmacology.

Dose‐dependent suppression of human photoparoxysmal response with the competitive AMPA/kainate receptor antagonist BGG492: Clear PK/PD relationship

B. Steinhoff, T. Mayer, F. Rosenow, 2015, Epilepsia.

A randomized, placebo‐controlled trial of AFQ056 for the treatment of chorea in Huntington's disease

R. Reilmann, L. Schöls, F. Gasparini, 2015, Movement disorders : official journal of the Movement Disorder Society.